SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-276965
Filing Date
2022-11-03
Accepted
2022-11-03 16:45:07
Documents
16
Period of Report
2022-11-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d417978d8k.htm   iXBRL 8-K 28550
2 EX-1.1 d417978dex11.htm EX-1.1 211170
3 EX-5.1 d417978dex51.htm EX-5.1 13496
7 GRAPHIC g417978g1103080349812.jpg GRAPHIC 1785
8 GRAPHIC g417978g49y19.jpg GRAPHIC 3060
  Complete submission text file 0001193125-22-276965.txt   451557

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA stsa-20221103.xsd EX-101.SCH 2864
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20221103_lab.xml EX-101.LAB 18739
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20221103_pre.xml EX-101.PRE 11713
10 EXTRACTED XBRL INSTANCE DOCUMENT d417978d8k_htm.xml XML 3465
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39041 | Film No.: 221358729
SIC: 2834 Pharmaceutical Preparations